News
Novo Nordisk names new CEO as the obesity drugmaker cuts sales, profit outlook
Novo Nordisk has named Maziar Mike Doustdar, currently the company’s EVP of international operations, as the new CEO. Doustdar will succeed Lars Fruergaard Jørgensen, whose surprise abdication was announced in May. Doustdar will assume the chief executive post on Aug. 7, a day after Novo reports its half-year performance, the company said Tuesday.
Knockoff copies of Novo’s weight loss medicine Wegovy have held back sales and put the drugmaker on the back foot in its ...
Ozempic and Wegovy maker Novo Nordisk sees shares tumble on profit alert - The Danish firm blamed the move to slash its ...
Novo Nordisk (NVO) stock falls as the company names a new CEO and cuts outlook citing pressure on obesity drug sales. Eli ...
In a surprise double announcement Tuesday, Novo reduced sales guidance by 5%—attributing the change to slowed growth of its ...
Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its ...
Novo Nordisk stock collapsed 26% in its worst trading day ever after slashing guidance on Wegovy sales and naming a new CEO.
The company has looked internally for its new leader, as Doustdar is currently serving as its head of international ...
Torrent Pharmaceuticals is preparing to introduce both oral and injectable versions of Semaglutide, a blockbuster diabetes ...
Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback